Granules India’s arm gets USFDA nod for ANDA

27 Nov 2018 Evaluate

The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules India’s subsidiary -- Granules Pharmaceuticals, through its US agent First Time US Generics LLC, for Methylphenidate Hydrochloride Extended-Release Tablets USP, 10 mg and 20 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug ‘Ritalin SR Sustained-Release Tablets, 20 mg’ of Novartis Pharmaceuticals Corporation. Granules Pharmaceuticals shall market and distribute the product shortly.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

578.15 13.20 (2.34%)
27-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1636.05
Dr. Reddys Lab 1240.00
Cipla 1313.20
Zydus Lifesciences 895.85
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×